Moleculin Biotech, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Moleculin Biotech, Inc. (MBRX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$33.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-18
- Moleculin Biotech, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$33.50M.
- Moleculin Biotech, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$25.86M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$33.50M 10-K · filed 2026-03-18 |
| 2024-12-31 | -$25.86M 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |